CAPTRUST Financial Advisors
RARE icon

CAPTRUST Financial Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$427K Buy
20,395
+9,017
+79% +$203K ﹤0.01% 2140
2025
Q4 		$262K Buy
11,378
+2,358
+26% +$77.5K ﹤0.01% 2348
2025
Q3 		$271K Buy
+9,020
New +$271K ﹤0.01% 2240
2024
Q4 		– Sell
-11,428
Closed -$635K – 2380
2024
Q3 		$635K Buy
11,428
+6,445
+129% +$328K ﹤0.01% 1453
2024
Q2 		$205K Buy
+4,983
New +$213K ﹤0.01% 2028
2024
Q1 		– Sell
-21,560
Closed -$1.03M – 2545
2023
Q4 		$1.03M Sell
21,560
-1,748
-7% -$67.8K ﹤0.01% 1248
2023
Q3 		$831K Sell
23,308
-1,532
-6% -$60.7K ﹤0.01% 1311
2023
Q2 		$1.15M Buy
+24,840
New +$1.15M ﹤0.01% 1125
2022
Q3 		– Sell
-404
Closed -$24K – 3586
2022
Q2 		$24K Buy
404
+145
+56% +$8.92K ﹤0.01% 3272
2022
Q1 		$19K Buy
259
+11
+4% +$765 ﹤0.01% 3423
2021
Q4 		$21K Buy
248
+114
+85% +$9.28K ﹤0.01% 3258
2021
Q3 		$12K Sell
134
-6
-4% -$542 ﹤0.01% 3504
2021
Q2 		$13K Sell
140
-534
-79% -$55.6K ﹤0.01% 3392
2021
Q1 		$77K Buy
674
+133
+25% +$18.1K ﹤0.01% 2139
2020
Q4 		$75K Buy
+541
New +$64.2K ﹤0.01% 1651

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CAPTRUST Financial Advisors's RARE Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 79% in Q1 2026, buying an estimated $203K and bringing the position to 20,395 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

CAPTRUST Financial Advisors first reported a position in RARE in Q4 2020 and has held it in 15 quarters since. The position peaked at $1.15M in Q2 2023. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • CAPTRUST Financial Advisors held 20,395 shares of Ultragenyx Pharmaceutical worth $427K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 9,017 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $203K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2140 holding.
  • CAPTRUST Financial Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 15 quarters since.
  • CAPTRUST Financial Advisors's Ultragenyx Pharmaceutical position peaked at $1.15M in Q2 2023.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.